These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26882172)

  • 1. Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement.
    Drzymała-Czyż S; Jończyk-Potoczna K; Lisowska A; Stajgis M; Walkowiak J
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):645-9. PubMed ID: 26882172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.
    Kappler M; Espach C; Schweiger-Kabesch A; Lang T; Hartl D; Hector A; Glasmacher C; Griese M
    Aliment Pharmacol Ther; 2012 Aug; 36(3):266-73. PubMed ID: 22670841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic therapy and fat digestion and absorption in cystic fibrosis.
    Lisowska A; Pogorzelski A; Oracz G; Skorupa W; Cofta S; Szydłowski J; Socha J; Walkowiak J
    Acta Biochim Pol; 2011; 58(3):345-7. PubMed ID: 21738905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis.
    Lepage G; Paradis K; Lacaille F; Sénéchal L; Ronco N; Champagne J; Lenaerts C; Roy CC; Rasquin-Weber A
    J Pediatr; 1997 Jan; 130(1):52-8. PubMed ID: 9003851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver disease does not affect lipolysis as measured with the 13C-mixed triacylglycerol breath test in children with cystic fibrosis.
    Ling SC; Amarri S; Slater C; Hollman AS; Preston T; Weaver LT
    J Pediatr Gastroenterol Nutr; 2000 Apr; 30(4):368-72. PubMed ID: 10776945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid digestion in cystic fibrosis: comparison of conventional and high-lipase enzyme therapy using the mixed-triglyceride breath test.
    De Boeck K; Delbeke I; Eggermont E; Veereman-Wauters G; Ghoos Y
    J Pediatr Gastroenterol Nutr; 1998 Apr; 26(4):408-11. PubMed ID: 9552136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
    Scher H; Bishop WP; McCray PB
    Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.
    Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A
    J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 13Carbon mixed triglyceride breath test and pancreatic enzyme supplementation in cystic fibrosis.
    Amarri S; Harding M; Coward WA; Evans TJ; Weaver LT
    Arch Dis Child; 1997 Apr; 76(4):349-51. PubMed ID: 9166030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
    Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
    J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.
    Merli M; Bertasi S; Servi R; Diamanti S; Martino F; De Santis A; Goffredo F; Quattrucci S; Antonelli M; Angelico M
    J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):198-203. PubMed ID: 7815243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
    Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
    Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up.
    van de Meeberg PC; Houwen RH; Sinaasappel M; Heijerman HG; Bijleveld CM; Vanberge-Henegouwen GP
    Scand J Gastroenterol; 1997 Apr; 32(4):369-73. PubMed ID: 9140160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between pancreatic lipase activity and gastric emptying rate in children with cystic fibrosis.
    Symonds EL; Omari TI; Webster JM; Davidson GP; Butler RN
    J Pediatr; 2003 Dec; 143(6):772-5. PubMed ID: 14657826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
    Lindblad A; Glaumann H; Strandvik B
    Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.
    Colombo C; Crosignani A; Battezzati PM; Castellani MR; Comi S; Melzi ML; Giunta A
    J Hepatol; 1999 Oct; 31(4):672-7. PubMed ID: 10551391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.